fadrozole fadrozole fadrozole (inn), sold under the brand name afema (by novartis), is a selective, nonsteroidal aromatase inhibitor which is or has been used in japan for the treatment of breast cancer. pharmacodynamics of aromatase inhibitors generationmedicationdosage % inhibitionaclassbic50c firsttestolactone250 mg 4x/day p.o. ?type i ? 100 mg 3x/week i.m. ? rogletimide200 mg 2x/day p.o.400 mg 2x/day p.o.800 mg 2x/day p.o.50.6%63.5%73.8%type ii ? aminoglutethimide250 mg mg 4x/day p.o.90.6%type ii4,500 nm secondformestane125 mg 1x/day p.o.125 mg 2x/day p.o.250 mg 1x/day p.o.72.3%70.0%57.3%type i30 nm 250 mg 1x/2 weeks i.m.500 mg 1x/2 weeks i.m.500 mg 1x/1 week i.m.84.8%91.9%92.5% fadrozole1 mg 1x/day p.o.2 mg 2x/day p.o.82.4%92.6%type ii ? thirdexemestane25 mg 1x/day p.o.97.9%type i15 nm anastrozole1 mg 1x/day p.o.10 mg 1x/day p.o.96.7–97.3%98.1%type ii10 nm letrozole0.5 mg 1x/day p.o.2.5 mg 1x/day p.o.98.4%98.9%–>99.1%type ii2.5 nm footnotes: a = in postmenopausal women. b = type i: steroidal, irreversible (substrate-binding site). type ii: nonsteroidal, reversible (binding to and interference with the cytochrome p450 heme moiety). c = in breast cancer homogenates. sources: see template. fadrozoleclinical datatrade namesafemaroutes ofadministrationby mouthdrug classaromatase inhibitor; antiestrogenatc codenonelegal statuslegal status in general: ℞ (prescription only) identifiers iupac name 4-(5,6,7,8-tetrahydroimidazopyridin-5-yl)benzonitrile cas number102676-47-1 yhydrochloride: 102676-31-3 ypubchem cid59693chemspider53850 nuniih3988m64puhydrochloride: h0q44h4ecq ykeggd02451 ychemblchembl9298 ncomptox dashboard (epa)dtxsid5034141 chemical and physical dataformulac14h13n3molar mass223.279 g·mol−13d model (jsmol)interactive image smiles c1cc(n2c=nc=c2c1)c3=cc=c(c=c3)c#n inchi inchi=1s/c14h13n3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14h,1-3h2 nkey:clpfflwzzbqmao-uhfffaoysa-n n ny (what is this?) (verify)